Altamira Therapeutics Ltd.
CYTONASDAQHealthcare
$0.30
+$0.30(+100.00%)
Market Cap$1133556
P/E Ratio—
52W High$0.4158
52W Low$0.3
Altamira Therapeutics Ltd. (CYTO) · Income Statement
Annual, quarterly, or TTM views · SEC 10-K & 10-Q via FMP · adjust period and M/B/T below.
FMP · CYTO · as of 2026-06-09
Financial statements
Revenue · Gross Profit · Net Income
| Breakdown | 2023-12 | 2022-12 | 2021-12 | 2020-12 | 2019-12 |
|---|---|---|---|---|---|
| Revenue | |||||
| Revenue | $0.00B | $0.00B | $0.00B | $0.00B | ($0.00B) |
| Cost of Revenue | $0.00B | $0.00B | $0.00B | $0.00B | $0.00B |
| Gross Profit | ($0.00B) | ($0.00B) | ($0.00B) | $0.00B | ($0.00B) |
| Gross Margin %(computed) | — | -372.36% | — | 100.00% | 100.00% |
| Operating Expenses | |||||
| R&D Expenses | $0.00B | $0.01B | $0.00B | $0.00B | $0.00B |
| G&A Expenses | $0.00B | $0.00B | $0.00B | $0.00B | $0.00B |
| Total Operating Expenses | $0.01B | $0.02B | $0.01B | $0.01B | $0.01B |
| Operating Income | ($0.01B) | ($0.02B) | ($0.01B) | ($0.01B) | ($0.01B) |
| Operating Margin %(computed) | — | — | — | — | — |
| Interest Income | $0.00B | $0.00B | $0.00B | $0.00B | $0.00B |
| Interest Expense | $0.00B | $0.00B | $0.00B | $0.00B | $0.00B |
| Income Before Tax | ($0.01B) | ($0.02B) | ($0.01B) | ($0.01B) | ($0.01B) |
| Income Tax Expense | $0.00B | ($0.00B) | ($0.00B) | ($0.00B) | ($0.00B) |
| Net Income | ($0.01B) | ($0.03B) | ($0.02B) | ($0.01B) | ($0.01B) |
| Net Margin %(computed) | — | — | — | — | — |
| Per Share & EBITDA | |||||
| EPS (Basic) | $-14.81 | $-582.58 | $-515.11 | $-545.41 | $-455.96 |
| Wtd Avg Shares | 0.00B | 0.00B | 0.00B | 0.00B | 0.00B |
| EBITDA | ($0.01B) | ($0.02B) | ($0.01B) | ($0.01B) | ($0.01B) |
| EBITDA Margin %(computed) | — | — | — | — | — |
Data source: Financial Modeling Prep · Last updated: 2026-06-09 · CHF · B
Explore more Altamira Therapeutics Ltd. data
About Altamira Therapeutics Ltd. (CYTO) Income Statement
Altamira Therapeutics Ltd. (CYTO) income statement data is sourced from SEC Form 10-K and 10-Q filings. For fiscal year 2023, CYTO reported revenue of $0.00B, gross profit of ($0.00B) (gross margin —), and net income of ($0.01B) — a net profit margin of —.
Frequently asked questions
CYTO · 4 questionsAltamira Therapeutics Ltd. (CYTO) reported revenue of $0.00B for 2023, down 100.0% year-over-year.
CYTO revenueCYTO salesannual revenue YoYincome statement
· Source: FMP /stable/income-statement · SEC EDGAR Form 10-K & 10-Q · As of 2026-06-09